Although CAR-T cell activity could be supplemented with inflammatory cytokines such as high dose IL-2, however, systemic IL-2 treatment induces severe capillary leak syndrome and eventually end-organ dysfunction. This evidence concerns the gene IL2 and capillary leak syndrome.